Skip to main content
SpringerLink
Log in

Clinical trial of pyridoxine to reduce vincristine neurotoxicity

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

In a murine model system, pyridoxine has demonstrated protective properties during administration of lethal doses of vincristine (VCR). Subsequently, pyridoxine has been evaluated in patients receiving VCR during an adjuvant chemotherapy program for stage II carcinoma of the breast. The toxicities, cumulative VCR dosage, and percentage of ideal dosage observed in 24 patients receiving pyridoxine have been compared to those observed in 88 patients who previously received VCR without pyridoxine in the same chemotherapy program. All patients ideally were to receive VCR 1.0 mg/m2 weekly for 6-weeks with dose modification for neurotoxicity. Treatment patients received pyridoxine 1.5 grams p.o. daily in three divided doses during the 6-week course. The degree of neurotoxic manifestations of VCR was similar in the treatment and comparison patients. Absent to mild neurotoxicity was observed in approximately 70% of patients in both groups; moderate or greater neurotoxicity occurred in about 30% of patients in both groups. Full dosage (6.0 mg/m2) was attained in 8 (33%) treatment patients and 18 (24%) comparison patients (p=0.28). The mean percentage of ideal dosage of VCR was 84.6±10.8 in patients receiving pyridoxine and 81.9±21.6 in those given only VCR (p=0.59). Gastrointestinal and hematologic toxicities were similar in both groups. Pyridoxine in this dose and schedule afforded no protection from the neurotoxic side effects of VCR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jackson DV, Bender RA: The clinical pharmacology of the vinca alkaloids, epipodophyllotoxins, and maytansine. In: Pinedo M (ed) Clinical pharmacology of anti-neoplastic drugs. Elsevier/North-Holland Biomedical Press, pp 277–294, 1978.

  2. Carbone PP, Bono V, Frei E III, Brindley CO: Clinical studies with vincristine. Blood 21:640–647, 1963.

    PubMed  Google Scholar 

  3. Holland JF, Scharlau C, Gailani et al: Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Res 33:1258–1264, 1973.

    PubMed  Google Scholar 

  4. Jackson DV, Sethi VS, Spurr CL et al: Intravenous vincristine infusion: phase I trial. Cancer 48:2559–2564, 1981.

    PubMed  Google Scholar 

  5. Kaplan RS, Wiernik PH: Neurotoxicity of antineoplastic drugs. Sem Onc 9:103–130, 1982.

    Google Scholar 

  6. Morgan SK, Grush OC: Vincristine toxicity treated with citrovorum factor rescue (Abstract). Clinic Res 26:82A, 1978

    Google Scholar 

  7. Jochimsen, PR: Subacute vincristine toxicity following five consecutive daily doses. Am J Clin Oncol: CCT 5:437–441, 1982.

    Google Scholar 

  8. Thomas LL, Braat PC, Somers R, Goudsmit R: Massive vincristine overdose: failure of leucovorin to reduce toxicity. Cancer Treat Rep 66:1967–1969, 1982.

    PubMed  Google Scholar 

  9. Wason S, Lacouture PG, Lovejoy FH: Single high-dose pyridoxine treatment for isoniazid overdose. JAMA 246:1102–1104, 1981.

    Article  PubMed  Google Scholar 

  10. Smith JP, Rutledge FN: Random study of hexamethylmelamine, 5-fluorouracil and melphalan in treatment of advanced carcinoma of the ovary. Natl. Cancer Inst Monogr 42:169–172, 1975.

    PubMed  Google Scholar 

  11. Jackson D, Long T, Rich C, Rardin D, McMahan R, Case D, Wells B, Capizzi R: Pyridoxine modification of vincristine toxicity (Abst). Proc Amer Assoc Cancer Res 25:313, 1984 (Presented at the seventy-fifth Annual Meeting of the American Association for Cancer Research, Toronto, Ontario, Canada, May, 1984).

    Google Scholar 

  12. Jackson DV, Case LD, White DR, Cooper MR, Stuart JJ, Muss HB, Richards F II, Hopkins JO, Atkins JN, Craig JB, Grimm RA, Spurr CL: Preliminary clinical trial of pyridoxine to reduce vincristine neurotoxicity (Abst). Clin Res 32:854A (Presented at the Joint Meeting of the Southern Society for Clinical Investigation and American Federation for Clinical Research, New Orleans, LA, February, 1985).

  13. Schaumburg H, Kaplan J, Windebank A, Vick N, Rasmus S, Pleasure D, Brown MJ: Sensory neuropathy from pyridoxine abuse: A new megavitamin syndrome. N Engl J Med 309:445–448, 1983.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology Research Center Bowman Gray School of Medicine, Wake Forest University, 27103, Winston-Salem, North Carolina

    Don V Jackson Jr, Ellen K Pope, Renee A McMahan, M Robert Cooper, James N Atkins, Richard D Callahan, Eugene H Paschold, Ruby A Grimm, Judith O Hopkins, Hyman B Muss, Frederick Richards II, John J Stuart, Douglas R White, Patricia J Zekan, Julia M Cruz, Charles L Spurr & Robert L Capizzi

  2. Piedmont Oncology Association, Bowman Gray School of Medicine, Wake Forest University, 27103, Winston-Salem, North Carolina

    Don V Jackson Jr, Ellen K Pope, Renee A McMahan, M Robert Cooper, James N Atkins, Richard D Callahan, Eugene H Paschold, Ruby A Grimm, Judith O Hopkins, Hyman B Muss, Frederick Richards II, John J Stuart, Douglas R White, Patricia J Zekan, Julia M Cruz, Charles L Spurr & Robert L Capizzi

Authors
  1. Don V Jackson Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ellen K Pope
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Renee A McMahan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Robert Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. James N Atkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Richard D Callahan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Eugene H Paschold
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ruby A Grimm
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Judith O Hopkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hyman B Muss
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Frederick Richards II
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. John J Stuart
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Douglas R White
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Patricia J Zekan
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Julia M Cruz
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Charles L Spurr
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Robert L Capizzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jackson, D.V., Pope, E.K., McMahan, R.A. et al. Clinical trial of pyridoxine to reduce vincristine neurotoxicity. J Neuro-Oncol 4, 37–41 (1986). https://doi.org/10.1007/BF02158000

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02158000

Keywords

Search

Navigation